Modification of cardiovascular responses to spinal GABAB receptor stimulation by cAMP and by KATP channel blockade in anaesthetized rats

Autonomic and Autacoid Pharmacology Pub Date : 2009-01-09 DOI:10.1111/j.1365-2680.1999.tb00007.x

H. C. Koh, I. C. Shin, J. H. Ha, D. J. Paik, J. S. Kang, C H. Lee

{"title":"Modification of cardiovascular responses to spinal GABAB receptor stimulation by cAMP and by KATP channel blockade in anaesthetized rats","authors":"H. C. Koh, I. C. Shin, J. H. Ha, D. J. Paik, J. S. Kang, C H. Lee","doi":"10.1111/j.1365-2680.1999.tb00007.x","DOIUrl":null,"url":null,"abstract":"<div>\n \n 1 Intrathecal (i.t.) injection of baclofen (30, 60 and 100 nmol), a GABAB receptor agonist, produced a dose-dependent decrease in blood pressure (BP) and heart rate (HR).\n 2 Pretreatment with 5-aminovaleric acid (50 nmol), a GABAB receptor antagonist, blocked the depressor and bradycardic effects of baclofen (100 nmol).\n 3 Pretreatment with 8-bromo-cAMP (10 nmol), a cAMP analogue, attenuated the depressor and bradycardic effects of baclofen (100 nmol), but not with 8-bromo-cGMP (10 nmol), a cGMP analogue.\n 4 In addition, pretreatment with glipizide (20 nmol), an ATP-sensitive K+ channel (KATP) blocker, attenuated the depressor and bradycardic effects of baclofen (100 nmol).\n 5 These results suggest that GABAB receptors in the spinal cord have an inhibitory role in the central cardiovascular regulation and that these depressive and bradycardic actions are modified by cAMP and by KATP channel blockade.\n </div>","PeriodicalId":100151,"journal":{"name":"Autonomic and Autacoid Pharmacology","volume":"19 6","pages":"347-352"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-2680.1999.tb00007.x","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autonomic and Autacoid Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2680.1999.tb00007.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

1 Intrathecal (i.t.) injection of baclofen (30, 60 and 100 nmol), a GABA_B receptor agonist, produced a dose-dependent decrease in blood pressure (BP) and heart rate (HR).

2 Pretreatment with 5-aminovaleric acid (50 nmol), a GABA_B receptor antagonist, blocked the depressor and bradycardic effects of baclofen (100 nmol).

3 Pretreatment with 8-bromo-cAMP (10 nmol), a cAMP analogue, attenuated the depressor and bradycardic effects of baclofen (100 nmol), but not with 8-bromo-cGMP (10 nmol), a cGMP analogue.

4 In addition, pretreatment with glipizide (20 nmol), an ATP-sensitive K⁺ channel (K_ATP) blocker, attenuated the depressor and bradycardic effects of baclofen (100 nmol).

5 These results suggest that GABA_B receptors in the spinal cord have an inhibitory role in the central cardiovascular regulation and that these depressive and bradycardic actions are modified by cAMP and by K_ATP channel blockade.

查看原文本刊更多论文

cAMP和KATP通道阻断对麻醉大鼠脊髓GABAB受体刺激后心血管反应的影响

鞘内注射巴氯芬(30,60和100 nmol)，一种GABAB受体激动剂，产生剂量依赖性的血压(BP)和心率(HR)降低。2 . GABAB受体拮抗剂5-氨基戊酸(50 nmol)预处理可阻断巴氯芬(100 nmol)的降压和心动过缓作用。3预处理8-溴-cAMP (10 nmol)， cAMP类似物，可以减弱巴氯芬(100 nmol)的抑制作用和心动过缓作用，但8-溴-cGMP (10 nmol)， cGMP类似物不能。4此外，格列吡嗪(20 nmol)预处理，一种atp敏感的K+通道(KATP)阻滞剂，减弱巴氯芬(100 nmol)的抑制作用和心动过缓作用。这些结果表明，脊髓中的GABAB受体在中枢心血管调节中具有抑制作用，这些抑制和心动过缓的作用被cAMP和KATP通道阻断所改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Autonomic and Autacoid Pharmacology

自引率

0.00%

发文量